Politics
FDA: Mifepristone review won’t be done until March
The Hill·October 8, 2026·1 min read
The FDA disclosed in a Wednesday court filing that its safety review of the abortion drug mifepristone will not be published until March, and it will impose no new restrictions on the pill before then. The delay is likely to anger anti-abortion activists who have grown impatient with the agency's timeline.
Read at The HillDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.